Takeda Enters CNS Collaboration with Wave Life Sciences; Amends Collaboration to Discontinue Discovery Research Component
Executive Summary
Takeda Pharmaceutical Co. Ltd. and Wave Life Sciences Ltd. entered into an option and license agreement focused on central nervous system disorders, including Huntington’s and Alzheimer’s diseases, amyotrophic lateral sclerosis (ALS), and dementia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice